Coronavirus vaccines developed in Japan are unlikely to become available for practical use until at least 2022, according to industry officials.
Only one company in Japan is conducting a trial of a vaccine.
Britain plans to start the distribution of a vaccine developed by U.S. pharmaceutical giant Pfizer Inc. and German partner BioNTech SE as early as next week.
AnGes Inc., a startup originating from Osaka University, leads in the vaccine development race in Japan.
In June, AnGes started a trial of a vaccine made from a copied part of the virus’ DNA. A second phase began last month.
The company initially aimed to receive approval for the vaccine next spring. But the timing is now uncertain as it needs to consider a trial covering several tens of thousands of people.
Shionogi & Co. is developing a vaccine with the COVID-19 antigen protein made with genetic engineering.
It aims to launch a trial by the end of this year and conduct a large-scale trial covering people in and outside Japan next year. The company plans to provide 30 million doses a year.
KM Biologics Co., a unit of food and pharmaceuticals group Meiji Holdings Co., and Daiichi Sankyo Co. are set to launch a trial in March next year.
ID Pharma Co., a unit of I’rom Group Co., which supports drug development, is expected to do so between March and May next year.
Foreign rivals lead the development of vaccines because know-how has been accumulated even in peacetime from the perspective of national security, an official at a major Japanese pharmaceutical firm said.
“We can make a vaccine for another coronavirus pandemic swiftly if we accumulate know-how,” a KM Biologics official said.
In a time of both misinformation and too much information, quality journalism is more crucial than ever.
By subscribing, you can help us get the story right.
Your news needs your support
Since the early stages of the COVID-19 crisis, The Japan Times has been providing free access to crucial news on the impact of the novel coronavirus as well as practical information about how to cope with the pandemic. Please consider subscribing today so we can continue offering you up-to-date, in-depth news about Japan.